Adlai Nortye (NASDAQ:ANL) Receives “Buy” Rating from HC Wainwright

by · The Markets Daily

Adlai Nortye (NASDAQ:ANL – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 28.04% from the company’s current price.

Several other brokerages have also issued reports on ANL. Loop Capital set a $49.00 target price on shares of Adlai Nortye in a research report on Tuesday. Oppenheimer initiated coverage on shares of Adlai Nortye in a report on Thursday, May 28th. They issued an “outperform” rating and a $32.00 target price on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Adlai Nortye in a report on Tuesday, July 14th. Cantor Fitzgerald initiated coverage on shares of Adlai Nortye in a research report on Monday, June 22nd. They set an “overweight” rating on the stock. Finally, Wall Street Zen raised Adlai Nortye from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $29.20.

View Our Latest Report on Adlai Nortye

Adlai Nortye Price Performance

ANL traded up $0.61 on Tuesday, reaching $15.62. The company had a trading volume of 122,782 shares, compared to its average volume of 385,536. Adlai Nortye has a 52-week low of $0.88 and a 52-week high of $17.25. The company has a current ratio of 9.55, a quick ratio of 0.65 and a debt-to-equity ratio of 0.04. The business has a 50 day simple moving average of $12.62 and a 200 day simple moving average of $11.42.

Insider Buying and Selling at Adlai Nortye

In related news, CFO Xiaofeng Ye sold 6,000 shares of Adlai Nortye stock in a transaction on Monday, August 24th. The stock was sold at an average price of $13.98, for a total transaction of $83,880.00. Following the transaction, the chief financial officer directly owned 153,424 shares in the company, valued at approximately $2,144,867.52. The trade was a 3.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Institutional Trading of Adlai Nortye

Several hedge funds have recently bought and sold shares of the stock. SmartHarvest Portfolios LLC raised its position in shares of Adlai Nortye by 8.5% during the 1st quarter. SmartHarvest Portfolios LLC now owns 16,367 shares of the company’s stock valued at $113,000 after buying an additional 1,279 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Adlai Nortye in the first quarter worth about $457,000. ADAR1 Capital Management LLC bought a new stake in shares of Adlai Nortye during the first quarter valued at approximately $816,000. Affinity Asset Advisors LLC purchased a new stake in shares of Adlai Nortye in the 1st quarter worth $1,140,000. Finally, Seven Fleet Capital Management LP bought a new position in Adlai Nortye during the 2nd quarter worth about $1,302,000. Hedge funds and other institutional investors own 35.21% of the company’s stock.

Adlai Nortye Company Profile

(Get Free Report)

Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.

Read More